Kornimate/medical-research-clean huggingface dataset:
the effects of lactose intolerance on gastrointestinal function and symptoms in a chinese population

Conditions: Lactose Intolerance; Irritable Bowel Syndrome

Summary: lactose is a carbohydrate found in milk,and lactase deficiency (ld) is a condition in which the small intestine cannot digest this carbohydrate due to absent or insufficient amounts of lactase.individuals with ld may be intolerant of lactose in the diet and experience abdominal cramps, bloating and diarrhea; however the response is variable.some tolerate moderate amounts of lactose without adverse effect,whereas others experience severe symptoms in response to even small doses. these problems may be representative of wider issues regarding individual tolerance to diet containing ubiquitous poorly absorbed, fermentable carbohydrates (such as: fructose, fructans)and be relevant to symptom generated in patients with diarrhea predominant irritable bowel syndrome (d-ibs). this project will investigate the effects of diet,lifestyle stress and psychiatric dietary on the development of functional gastrointestinal symptoms. lactose will be used to assess tolerance to dietary challenge, a test that is particularly relevant in a chinese population with a high prevalence of lactase deficiency.

study #1: questionnaire study in general chinese population (n=2000). study #2: physiologic study in patients attending gastroenterology clinic (n=600) including in subgroups assessment of genetic factors,tolerance to lactose challenge and assessment of visceral sensitivity. study #3: assessment of appropriate dosage of lactose hydrogen breath test in a population with high-prevalence of lactase deficiency. study #4: impact of a determined dietary intervention on abdominal symptoms compatible with d-ibs. study #5: the association of visceral sensitivity induced by li with mucosal immune activation and psychological factors in d-ibs patients

Eligibility criteria:
inclusion criteria: 1. aged at least 16 years old and not more than 75 years old. 2. ability to communicate with the investigator, complete study questionnaires (with help of investigator) and provide informed consent. exclusion criteria: 1. progressive, severe disease requiring active medical management (e.g. advanced cardiac, liver, renal or neurological disease, advanced cancer) 2. history of significant gastrointestinal pathology (other than gastro-oesophageal reflux disease and functional bowel diseases) 3. history of gastro-intestinal surgery (except appendicectomy, cholecystectomy, hernia repair). 4. evidence of active drug or alcohol abuse

Keywords: lactose intolerance dna sequencing psychosocial factors irritable bowel syndrome visceral hypersensitivity
autologous plasma rich in growth factors (prgf) treating the symptomatic knee oa

Conditions: Joint Disease

Summary: the purpose of this study is to evaluate the efficacy and safety of prgf infiltrations in the treatment of knee osteoarthritis.

several studies have shown the positive effects of the autologous "preparation rich in growth factors" (prgf) in different clinical situations involving connective tissues and also in oa synovial cells. prgf is a biological delivery system of a complex mixture of bioactive proteins essential to natural repair including anabolic factors for cartilage such as transforming growth factor-β1 (tgf-β1), platelet-derived growth factor (pdgf) and insulin-like growth factor (igf-i). the potential of prgf to enhance the limited capacity of cartilage to repair itself encouraged the idea of treating degenerative joint conditions with this autologous preparation. the present study was undertaken to assess the efficacy and safety of the intra-articular injection of prgf and to obtain useful information about the clinical effects. since pain is the most pressing problem facing people with oa, a significant improvement in pain would indicate the potential of the proposed treatment. we will also evaluate functionality and quality of life. in addition we will examine changes in novel serum and synovial fluid biomarkers and their correlation with mri-based parameters in a subgroup of patients.

Eligibility criteria:
inclusion criteria: * patients of both sexes and aged between 40 and 72 years. * diagnosed with osteoarthritis of the knee by radiological image. * pain in the joint equal to or greater than 2.5 points in eav. * radiological severity:value in the ahlback score 3 or less. * body mass index between 20 and 30. * possibility for observation during follow-up period. exclusion criteria: * bilateral gonarthrosis requiring infiltration in both knees. * body mass index greater than 30. * diagnosed polyarticular disease. * severe mechanical deformation. * previous arthroscopy in the past year. * intraarticular infiltration of hyaluronic acid in the last 6 months. * rheumatic autoimmune systemic disease. * poorly controlled diabetes mellitus. * blood alterations. * immunosuppressive treatments and/or coumarinics. * treatment with steroids for 3 months prior to its inclusion in the study. * treatment with nonsteroidal anti-inflammatory drugs for 15 days prior to its inclusion in the study.

Keywords: osteoarthritis knee prgf autologous plasma plasma preparations treatment
profonycia - honey for improving quality of patient's life receiving chemotherapy

Conditions: Myelosuppression

Summary: myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor. death occurring after chemotherapy usually results either from infection related to drug induced leucopenia or from bleeding related to thrombocytopenia. colony stimulating factors (csfs) are widely used in the treatment of chemotherapy induced neutropenia. the same erythropoetines are used in the treatment of chemotherapy induced anemia. both treatments are expensive and have several side effects. in our previous stud (1) we found a special kind of honey: life-mel honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life. the aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary csf administration in patients receiving chemotherapy along with a natural and non expensive honey: profonycia. this honey which is expressed in kibutz shamir in upper galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.


Eligibility criteria:
inclusion criteria: patients 18 years old or elder receiving chemotherapy 1/2-3 weeks exclusion criteria: patients below 18 years old

Keywords: myelosuppression, chemotherapeutic agents, leucopenia, thrombocytopenia, profonycia
irreversible electroporation(ire) for unresectable hilus pulmonis neoplasms

Conditions: Hilus Pulmonary Neoplasms

Summary: the purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (ire) for hilus pumonis neoplasms.

by enrolling patients with unresectable head and hilus pulmonis adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous ire for unresectable hilus pulmonis neoplasms.

Eligibility criteria:
inclusion criteria: * hilus pumonis neoplasms diagnosed by positive biopsy or non-invasive criteria, * not suitable for surgical resection, * eastern cooperative oncology group (ecog) score of 0-1, * a prothrombin time ratio \> 50%, * platelet count \> 80x10\^9/l, * ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post nanoknife procedure, * able to comprehend and willing to sign the written informed consent form (icf), * have a life expectancy of at least 3 months. exclusion criteria: * cardiac insufficiency, ongoing coronary artery disease or arrhythmia, * any active implanted device (eg pacemaker), * women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception, * have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the nanoknife™ ledc system, * are in the opinion of the investigator unable to comply with the visit schedule and protocol evaluations.

Keywords: irreversible electroporation hilus pulmonary neoplasms
implementation of the care ecosystem training model for individuals with dementia in a high-risk, integrated care management

Conditions: Dementia; Alzheimer Disease

Summary: there is growing need for to provide high quality care for persons living with dementia (plwd) and provide support for care partners in the primary care setting. the care ecosystem model is a telephone-based dementia care program that provides standardized, proactive, personalized, and scalable support and education for care partners. the care ecosystem model has demonstrated an improvement in patient quality of life, reduced unnecessary healthcare expenditures, and a decrease in care partner burden and depression. in this pilot the investigators will assess the feasibility of implementing and measuring outcomes of an adapted care ecosystem training model for primary care nurse managers serving a diverse panel of plwd and their care partners in primary care practices participating in the mass general brigham healthcare system's integrated care management program in boston, ma. the study team will leverage the mass general brigham electronic medical record to determine the feasibility of collecting the primary clinical outcome defined as emergency department visits among the plwd cared for by the primary care practices. the investigative team will also assess the feasibility of implementation, number of contacts between nurse care managers and care partners, and documented advance care planning.


Eligibility criteria:
inclusion criteria: * medicare beneficiary aligned to the partners medicare aco * icd-10 diagnosis code consistent with dementia in medicare claims between august 1, 2019 and july 31, 2020 (excluding diagnoses for diagnostic testing services) * actively engaged in care management services with a nurse care manager enrolled in the study exclusion criteria: - permanent resident of long-term care or deceased at the start of the study
connective tissue motion measure

Conditions: Low Back Pain

Summary: the goal of this project is to develop a biomarker - the connective tissue motion measure (ctmm) -quantifying the functional behavior of perimuscular connective tissues.

the differential motion between specific connective tissue strata will be measured during tissue displacement (linear oscillation) initiated by a computer-controlled needle stimulus tool (nst). the ctmm will be suitable as an outcome measure for mechanistic and clinical studies of cam interventions. the ctmm also will potentially serve as a clinical diagnostic and treatment-monitoring tool for manual therapists, acupuncturists, and cam clinicians interested in assessing the functional status of a patient's connective tissue.

Eligibility criteria:
inclusion criteria for lbp subjects: * history of recurrent or chronic lbp for a minimum of 12 months * ability to stand and walk without assistance * ability to understand and read english * ability to understand and sign a consent form inclusion criteria for no-lbp subjects: * no history of low back pain or any other chronic pain that has limited activities of daily living or work * a numerical current pain index of less than 0.5. exclusion criteria for all subjects: * previous severe back or low extremity injury or surgery * major structural spinal deformity (scoliosis, kyphosis, stenosis) * ankylosing spondylitis or rheumatoid arthritis * neurological deficit (weakness and/or sensory loss, decreased deep tendon reflexes suggesting nerve root compression, but not subjective symptoms of nerve root irritation (sciatica) * neurological or major psychiatric disorder * bleeding disorders * corticosteroid or anticoagulant medication * pregnancy * worker's compensation or disability case * in litigation for the lbp problem * acute systemic infection * bmi less than 21 or greater than 35
efficacy and safety of apremilast in combination with nbuvb and nbuvb alone in vitiligo patients

Conditions: Vitiligo

Summary: patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the opd, dermatology department. it\&#39;s an interventional study where group a patient will be given nbuvb and tab apremilast 30 mg twice a day and group b will receive nbuvb alone.

patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the opd, dermatology department dow university hospital. informed consent will be obtained from all the patients. demographic details of patients including age, gender, education, occupation and marital status will be obtained. further each patient will be asked about duration of vitiligo and any systemic medications used by the patients in the last 6 months will be recorded. body surface area will be calculated and patients with \&gt; 5% of bsa will be included in the study. subjects will be randomly divided by lottery method into two groups. group a patients will be given nbuvb and tab apremilast 30 mg twice a day, and group b patients will receive nbuvb alone. hematological baseline including cbc and lfts will be advised to patients in group a. vitiligo area severity index (vasi) will be used to initially assess the patient at the baseline and later on to assess the regimentation in each of the patients of vitiligo on next 4 follow-ups. each follow-up will be after every 8 weeks for a total of 32 weeks. cbc and lfts will be repeated in group a after 4 weeks of starting tab apremilast 30 mg bd and then after 3 months. any side effects seen during the study period will be recorded and managed accordingly dlqi dermatological life quality index (dlqi) questionnaire will be conducted with 30 vitiligo patients at the baseline and at the end of therapy. all results will be collected and filled in proforma by the researcher. the results will be assessed statistically at the end of the follow-up period.

Eligibility criteria:
inclusion criteria: * patients age 18 years and above * patients of both genders (male and female) * diagnosed patients of non-segmental vitiligo involving \> 5% of bsa exclusion criteria: * pregnant and lactating women * concomitant active infection like tuberculosis * personal history of cutaneous malignancy * use of apremilast in the past 4 weeks * use of phototherapy within 4 weeks before randomization
does transfer of poor-quality embryos with good-quality embryos improve pregnancy outcome in women undergoing ivf/icsi?

Conditions: Infertility

Summary: women planned to undergo blastocyst-stage embryo transfer after ivf/icsi were randomized into 2 groups: * group i: women who had only good-quality embryo transfer. * group ii: women who had both good-quality and poor-quality embryo transfer. primary outcome was ongoing clinical pregnancy rate


Eligibility criteria:
inclusion criteria: * women undergoing primary ivf/icsi cycles for tubal factor/unexplained infertility and had blastocyst-stage et exclusion criteria: * cleavage-stage et. * women who had no good-quality embryos to transfer * women who had known poor endometrial receptivity
effects of swiss ball vs frenkle exercises on static and dynamic balance in ataxic cp

Conditions: Cerebral Palsy

Summary: several studies have highlighted the significant impact of cerebral palsy, a prevailing neurological and musculoskeletal developmental disorder among childhood disabilities worldwide. within the spectrum of cerebral palsy, ataxic cp stands as the least prevalent type, accounting for 5 to 10% of all cases. individuals diagnosed with ataxic cp encounter difficulties in fine motor skills, precision, and coordination, and exhibit an unsteady gait, some of which are linked to compromised postural control and inadequate core stability. these issues culminate in functional limitations, heightening the risk of falls, and further contributing to the overall disability experienced by the patients. consequently, there exists a need to prioritize research and develop targeted treatment protocols specifically for ataxic cp. it is crucial to emphasize the enhancement of postural control and coordination, with particular emphasis on improving static and dynamic balance during rehabilitation. implementing swiss ball exercises and frenkel exercises in the rehabilitation protocol for children with ataxic cerebral palsy can significantly diversify treatment strategies. these exercises play a pivotal role in supporting these children to either sustain or regain their ability to function independently, reduce the risk of falls, and notably improve their overall well-being.

a four-week randomized clinical trial will involve 18 participants, divided randomly into two intervention groups, with nine participants in each group. group a (intervention group 1) will participate in swiss ball exercises combined with stretching, while group b (intervention group 2) will partake in frenkel exercises along with stretching. the sampling method employed will be a non-probability technique. the pediatric balance scale (pbs) will serve as the primary tool for outcome measurement. randomization will be conducted using computer-generated software. the study design will be single-blinded, ensuring the assessor remains unaware of the groups\&#39; assignments. initial data collection (pretest) will occur at week 0, followed by post-test data collection at week 4. for intergroup analysis, if the data follows a normal distribution, the parametric independent t-test will be utilized, enabling the calculation of mean, standard deviation, and p-values. alternatively, if the data does not display a normal distribution, the non-parametric mann-whitney test will be employed, allowing the calculation of median, interquartile ranges, and p-values.

Eligibility criteria:
inclusion criteria: * patients with having diagnosis of ataxic cerebral palsy * age between 5 to 8 years. * gmfc level 2. * both the genders were included exclusion criteria: * visual impairments and hearing loss * mental retardation * fixed contractures or deformities of the spine or extremities * meningitis

Keywords: cerebral palsy ataxic balance pediatric balance scale swiss ball frenkel
functional activity strength training

Conditions: Walking, Difficulty

Summary: this study is a randomized trial of 100 older adults with mobility disability, who performed a similar brief daily, resistance training program. the investigators set out to answer the following question "will a digital, brief daily exercise program be feasible, acceptable, and effective among older adults with walking limitations?" to answer that question, participants were assigned to an intervention or delayed-treatment control group. intervention participants were assigned to complete two 30-second lower body exercises and two 30-second upper body exercises. fitness tests were completed remotely three times during the 12-weeks (i.e., at baseline, week 6, week 12).

this is a 12-week delayed-control randomized trial to answer the following question "will a digital, brief daily exercise program be feasible, acceptable, and effective among older adults with walking limitations?" participants who screen eligible will be assigned to one of four conditions, an immediate workout group, an immediate workout group with activity monitor, a delayed workout group or a delayed workout group with activity monitor. participants will complete a daily 2.5-to-3.5-minute exercise routine at home and to record their results using an electronic survey. other outcome measurements will be conducted remotely at baseline, 6, and 12 weeks. the investigators hypothesize that participants in the amrap condition will report significant reductions in functional physical limitations, increased gait speed, and increased physical performance (i.e., increased exercise repetitions) from baseline to 6 weeks compared to those randomized to the delayed-treatment control.

Eligibility criteria:
inclusion criteria: * age 65 and older * difficulty with walking * providers must provide consent for their patient * access to the internet * must have a camera on computer, tablet, or smartphone * fluent in egnlish exclusion criteria: * chest pain or a heart condition on the par-q * planning to have surgery in the next 3 months * cognitive impairment * unable to exercise * being currently physically active
a real-world study: efficacy and safety of anlotinib for advanced non-small cell lung cancer(nsclc)

Conditions: NSCLC

Summary: a real-world study: efficacy and safety of anlotinib for advanced non-small cell lung cancer：this study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.

a real-world study: efficacy and safety of anlotinib for advanced non-small cell lung cancer：this study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.this study is a non-interventional, prospective, observational, real-world case study and all registered data are collected from real clinical practice cases. adult patients diagnosed as advanced non-small cell lung cancer and treated with anlotinib were included. at least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.the primary endpoint was progression-free survival (pfs) and the secondary endpoints included overall survival (os), objective response rate (orr), disease control rate (dcr) and safety.if the last patient reaches the main evaluation index or has intolerable toxic reaction, the observation will be finished, and the first one will prevail.through electronic data capture system (edc) system, electronic case report form (ecrf) is used to replace paper-based case report form to collect and manage clinical trial data.

Eligibility criteria:
inclusion criteria: 1. age: ≥18 years old, no gender limit. 2. diagnosed as advanced non-small cell lung cancer. 3. at least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm. 4. doctors evaluate the benefits of receiving anlotinib treatment. 5. the patient voluntarily joins the project and signs the informed consent. if any of the above items is "no", the patient is not suitable for this study. exclusion criteria: 1. those who have been confirmed to be allergic to anlotinib and/or its excipients. 2. patients with anlotinib contraindications.

Keywords: nsclc anlotinib pfs
sars-cov2 (covid-19) seroepidemiological transplanted subjects (kidney, kidney-pancreas, pancreas, langerhans islets)

Conditions: Kidney Transplant; Pancreatic Transplat; Pancreatic Islets Langerhans

Summary: evaluate sars-cov2 infection and the degree of immunity possibly developed in transplanted population using the luciferase immuno precipitation system (lips) test.


Eligibility criteria:
inclusion criteria cohort 1: * adult patients (age ≥ 18 years), * kidney or pancreas or pancreatic islets transplantation * transplanted patients (period: 01.01.2020 to 30.06.2020) * informed consent signed inclusion criteria cohort 2: * adult patients (age ≥ 18 years), * kidney or pancreas or pancreatic islets transplantation * transplanted patients in follow-up since 01.01.2020 or trasplanted patients after 30.06.2020. * informed consent signed exclusion criteria both cohort (1\&2): symptomatology such as fever\> 37.5, and / or cough and / or respiratory distress and / or diarrhea / vomiting in 14 days prior to collection of blood sample

Keywords: covid-19 infection transplanted patients kidney transplants pancreas transplants pancreatic islet transplantation